Patient and public involvement in health technology assessment: a new dawn?

12 April 2021 - Patient and public involvement and engagement have become increasingly embedded in health technology assessment over the last ...

Read more →

TLV subsidises melatonin for children and adolescents with ADHD

26 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, grants a subsidy for the drug Melatonin AGB ...

Read more →

Too high price for drugs for cystic fibrosis

25 March 2021 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, says no to subsidising the drugs Kaftrio and Kalydeco ...

Read more →

Health economic assessment of Zolgensma in spinal muscular atrophy

12 March 2021 - TLV has produced a health economic assessment for the regions for Zolgensma (onasemnogene abeparvovec) in the treatment ...

Read more →

Discounting in economic evaluation of health care interventions: what about the risk term?

13 March 2021 - Results from economic evaluations of long-term outcomes are strongly dependent on the chosen discount rate.  ...

Read more →

TLV is tasked with reducing costs for medicines

16 February 2021 - The Government has commissioned the Swedish Dental and Pharmaceutical Benefits Agency, TLV, to implement measures to reduce ...

Read more →

On the role of cost effectiveness thresholds in health care priority setting

25 January 2021 - In the past few years, empirical estimates of the marginal cost at which health care produces a ...

Read more →

Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration

18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...

Read more →

Reimbursement from pharmaceutical companies decreases by 288 million

11 December 2020 - The rebate from side agreements between regions and pharmaceutical companies is estimated according to the forecast ...

Read more →

TLV wants to go further with combination treatments in the field of cancer

7 December 2020 - Part of the solution for more patients to have access to combination treatments may be to create ...

Read more →

New report on TLV's medical technology assignment

3 December 2020 - In a new report, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reports on the work that ...

Read more →

Health economic assessment of Beovu in wet age-related macular degeneration

4 December 2020 - TLV has produced a health economic assessment for the regions for Beovu (brolucizumab). ...

Read more →

Takhzyro is not included in the high-cost protection

26 November 2020 - Takhzyro (lanadelumab) is a subcutaneous injection intended for routine prevention of recurrent hereditary seizures, angioedema in patients ...

Read more →

Rinvoq continues to be part of the high-cost protection with limited subsidy after reconsideration

25 November 2020 - TLV has reconsidered the subsidy for Rinvoq (upadacitinib monohydrate) and decided that the drug should continue to ...

Read more →

Additional analysis of Kyprolis in the treatment of multiple myeloma

6 November 2020 - TLV has performed an additional analysis of Kyprolis (carfilzomib) when used in combination with lenalidomide and dexamethasone ...

Read more →